EGFR and breast carcinoma: Although previous studies have revealed many potential biomarkers associated with poor prognosis in basal-like breast cancer, including basal cytokeratins (CK5/6, CK14, CK17), epidermal growth factor receptor (EGFR), c-kit, P63, P-cadherin and FOXC1, currently, there are no targeted treatments.